N-MYCIN
Natamycin
5%
Sterile
Ophthalmic Suspension
Description:
N-Mycin is
sterile ophthalmic suspension containing natamycin, which
appears to be fungicidal.
Composition:
Each ml contains natamycin
USP 50 mg.
Pharmacology:
Natamycin exerts
its antifungal activity by destroying the fungal cell membrane.
Indications:
N-Mycin
sterile ophthalmic suspension is indicated for the treatment
of fungal blepharitis, conjunctivitis and keratitis caused
by susceptible organisms including Fusarium solani.
Dosage & Administration:
For fungal
keratitis: The preferred initial dosage is 1 drop
instilled in the conjuntival sac (s) at 1-2 hours interval.
The frequency of application can usually be reduced to 1 drop
6-8 times daily after the first 3-4 days. Therapy should generally
be continued for 14 to 21 days or until there is resolution
of active fungal keratitis. In many cases, it may be helpful
to reduce the dosage gradually at 4 to 7 days intervals to
assure the replicating fungus has been eliminated.
For fungal
blepharitis & conjunctivitis: Less frequent initial
dosage, 1 drop 4-6 times daily may be sufficient.
Contraindications:
Natamycin sterile
ophthalmic suspension is contraindicated in individuals with
a known hypersensitivity to any of its components.
Contraindications:
Natamycin sterile
ophthalmic suspension is contraindicated in individuals with
a known hypersensitivity to any of its components.
Side Effects:
Local irritation,
conjunctival chemosis, hyperemia, etc.
Precautions & Warnings:
For topical eye use only. Failure of improvement of keratitis
following 7-10 days of administration of the drug suggests
that the infection may be caused by a microorganism not susceptible
to natamycin.
Use
in Pregnancy:
Pregnancy Category
C: N-Mycin sterile ophthalmic suspension should be given to
a pregnant woman only if clearly needed.
Use
in Nursing Mothers:
It is not known
whether this drug is excreted in human milk. Caution should
be exercised when natamycin is administered to a nursing mother.
Pediatric
Use:
Safety and effectiveness
in paediatric patients have not been established.
Storage:
